Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QDPR | P09417 | 3/20 | 0.65 |
| ▸ | HTR6 | P50406 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4233609 | 0.80 | SIGMAR1 (0.60) | SIGMAR1 | |
| SCHEMBL23448820 | 0.80 | QDPR (0.56) | QDPR | |
| SCHEMBL7229539 | 0.80 | ALDH1A1 (0.50) | QDPRSIGMAR1 | |
| SCHEMBL4233673 | 0.80 | SIGMAR1 (0.52) | SIGMAR1 | |
| SCHEMBL4231835 | 0.80 | KCNH2 (0.52) | QDPRSIGMAR1 | |
| Fumaric Acid SCHEMBL11554241 | 0.80 | QDPR (0.59) | QDPRHTR6 | |
| Maleic Acid SCHEMBL11554237 | 0.80 | QDPR (0.59) | QDPRHTR6 | |
| SCHEMBL13490343 | 0.79 | P4HA1 (0.51) | QDPRHTR6 | |
| SCHEMBL13898494 | 0.79 | QDPR (0.68) | QDPRHTR6 | |
| SCHEMBL8382616 | 0.79 | QDPR (1.00) | QDPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230127046-A1 | G9a INHIBITOR | RIKEN (JP) | 2023-04-27 | — | — | US | disclosed |
| US-20230127046-A1 | G9a INHIBITOR | RIKEN (JP) | 2023-04-27 | — | — | US | disclosed |
| US-20230127046-A1 | G9a INHIBITOR | RIKEN (JP) | 2023-04-27 | — | — | US | disclosed |
| EP-4066896-A1 | G9A INHIBITOR | RIKEN (JP) | 2022-10-05 | — | — | EP | disclosed |
| WO-2021106988-A1 | G9a INHIBITOR | 杏林製薬株式会社 | 2021-06-03 | — | — | WO | disclosed |
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
| US-20090029979-A1 | 5-HTX MODULATORS | BIO-MEDISINSK INNOVASJON AS (NO) | 2009-01-29 | — | — | US | disclosed |
| US-20090029979-A1 | 5-HTX MODULATORS | BIO-MEDISINSK INNOVASJON AS (NO) | 2009-01-29 | — | — | US | disclosed |
| WO-2007007072-A1 | 5-HTX MODULATORS | BIO-MEDISINSK INNOVASJON AS (NO) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029979-A1 | 5-HTX MODULATORS | HTR7, HTR5A, HTR2C | QDPR 535/4885HTR6 8/4885SIGMAR1 161/4885 |
| US-20230127046-A1 | G9a INHIBITOR | EZH2, BMI1, DOT1L | QDPR 3090/4885HTR6 3379/4885SIGMAR1 2525/4885 |
| US-20090233910-A1 | Npy antagonists, preparation and uses | NPY1R, NPY5R, NPY2R | QDPR 248/4885HTR6 176/4885SIGMAR1 303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.